- Home
- OPHC vs STTK Comparison
OPHC vs STTK Comparison
Compare OPHC & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- STTK
- Stock Information
- Founded
- OPHC 2000
- STTK 2016
- Country
- OPHC United States
- STTK United States
- Employees
- OPHC N/A
- STTK N/A
- Industry
- OPHC Major Banks
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- OPHC Finance
- STTK Health Care
- Exchange
- OPHC Nasdaq
- STTK Nasdaq
- Market Cap
- OPHC 49.0M
- STTK 54.4M
- IPO Year
- OPHC N/A
- STTK 2020
- Fundamental
- Price
- OPHC $4.94
- STTK $1.16
- Analyst Decision
- OPHC Hold
- STTK Hold
- Analyst Count
- OPHC 1
- STTK 3
- Target Price
- OPHC $5.25
- STTK $2.00
- AVG Volume (30 Days)
- OPHC 80.4K
- STTK 332.9K
- Earning Date
- OPHC 11-08-2024
- STTK 11-14-2024
- Dividend Yield
- OPHC N/A
- STTK N/A
- EPS Growth
- OPHC 78.77
- STTK N/A
- EPS
- OPHC 1.32
- STTK N/A
- Revenue
- OPHC $34,509,000.00
- STTK $6,435,000.00
- Revenue This Year
- OPHC N/A
- STTK $313.04
- Revenue Next Year
- OPHC N/A
- STTK N/A
- P/E Ratio
- OPHC $3.64
- STTK N/A
- Revenue Growth
- OPHC 66.69
- STTK 382.75
- 52 Week Low
- OPHC $3.74
- STTK $0.94
- 52 Week High
- OPHC $5.90
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- OPHC 53.11
- STTK 44.02
- Support Level
- OPHC $4.84
- STTK $1.07
- Resistance Level
- OPHC $5.04
- STTK $1.38
- Average True Range (ATR)
- OPHC 0.11
- STTK 0.12
- MACD
- OPHC -0.01
- STTK 0.01
- Stochastic Oscillator
- OPHC 60.47
- STTK 27.88
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides a range of community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal account, money market deposit accounts, debit cards, and automated teller machines.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.